US OptionsDetailed Quotes

PYXS241220P5000

Watchlist

3.16
+0.51+19.25%

15min DelayClose Nov 22 16:00 ET

3.30High3.15Low

Pyxis Oncology Stock Discussion

Jaguar8

Nov 21 12:57

This is the complete Preliminary PYX-201 Trial. There was NO death reported in this trial

$Pyxis Oncology (PYXS.US)$
This is the PYXS entire press release from its website
pyxisoncology.c...
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
PDF Version
— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line combo ther...

72641842

Nov 21 06:50

$Pyxis Oncology (PYXS.US)$ just posting this because it hasn't been talked about yet but the reason it's down is someone died during their trial. Most likely due to late stage cancer not because of the drug. Not a doctor. No position. Should bounce back though if this is the case imo. Good luck all!

Jaguar8

Nov 20 17:26

On watch tomorrow. Reason: Preliminary Phase 1 fair result. Badly beaten by Satan’s cohorts 😂 SI 14.89%

$Pyxis Oncology (PYXS.US)$

Abela

Nov 20 16:16

$Pyxis Oncology (PYXS.US)$ I think it will get back to 3+ by tomorrow

Jaguar8

Nov 20 16:05

I think they are up to my challenge 😂😂😂

$Pyxis Oncology (PYXS.US)$

Abela

Nov 20 15:48

$Pyxis Oncology (PYXS.US)$ boy I put my buy order at 3.50 and came back it hit 1.92😱😱😱 thanks to moomoo i didn't change the order into post market and skiped the massacre 🙏🙏🙏

Jaguar8

Nov 20 15:31

Hey shorts, why don’t you bring it down to 1? I challenge you 😂😆

$Pyxis Oncology (PYXS.US)$

Trytosaveabit

Nov 20 15:29

Hehehe

$Pyxis Oncology (PYXS.US)$ It dropped over 100% from AM high in less than 10 minutes! Sorry but thats not normal on this news!

Jaguar8

Nov 20 15:25

And Satan’s cohorts strike again 😈

$Pyxis Oncology (PYXS.US)$

Trytosaveabit

Nov 20 15:19

New 8K with a bit more!

$Pyxis Oncology (PYXS.US)$ Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
•
PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line combo therapy expansion trials to begin dosing 1Q25
•
Overall, 26% ORR across six Solid Tumor Types of Interest (n=31) with Dose Dependent Responses Observed, Sup...

No comment yet